NCT05517330View on ClinicalTrials.gov

Neoadjuvant Tislelizumab With Afatinib for Resectable Head and Neck Squamous Cell Carcinoma

PHASE2CompletedINTERVENTIONAL

Enrollment

23

Participants

Timeline

Start Date

September 19, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

July 31, 2024

Conditions

Head and Neck Cancer

Interventions

BIOLOGICAL

Tislelizumab

200mg IV Q3W

DRUG

Afatinib

30mg PO QD

Trial Locations (1)

610041

Xingchen Peng, Chengdu

All Listed Sponsors

lead

West China Hospital

OTHER